Home >> Pharmaceuticals >> Food & Beverage >>

Immunovaccine, Inc. - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 49 | Code: MRS - 35137

Immunovaccine, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Immunovaccine, Inc. - Product Pipeline Review - 2015’, provides an overview of the Immunovaccine, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunovaccine, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immunovaccine, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immunovaccine, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immunovaccine, Inc.’s pipeline products

Reasons to buy

- Evaluate Immunovaccine, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immunovaccine, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immunovaccine, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immunovaccine, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunovaccine, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Immunovaccine, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Immunovaccine, Inc. Snapshot 5
Immunovaccine, Inc. Overview 5
Key Information 5
Key Facts 5
Immunovaccine, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Immunovaccine, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Immunovaccine, Inc. - Pipeline Products Glance 15
Immunovaccine, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Immunovaccine, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Immunovaccine, Inc. - Drug Profiles 19
DPX-0907 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
DPX-Survivac 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
DPX-RSV 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Vaccine for Cocaine Addiction 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
DPX-Ebola 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
hepatitis B vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
influenza [strain H5N1] vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
malaria vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
pertussis (acellular) vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
dengue vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
herpes simplex virus [type 2] vaccine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
marburg vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
tuberculosis vaccine 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Immunovaccine, Inc. - Pipeline Analysis 36
Immunovaccine, Inc. - Pipeline Products by Target 36
Immunovaccine, Inc. - Pipeline Products by Route of Administration 37
Immunovaccine, Inc. - Pipeline Products by Molecule Type 38
Immunovaccine, Inc. - Recent Pipeline Updates 39
Immunovaccine, Inc. - Dormant Projects 45
Immunovaccine, Inc. - Discontinued Pipeline Products 46
Discontinued Pipeline Product Profiles 46
Subunit Vaccine for Pseudomonas 46
Immunovaccine, Inc. - Locations And Subsidiaries 47
Head Office 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Immunovaccine, Inc., Key Information 5
Immunovaccine, Inc., Key Facts 5
Immunovaccine, Inc. - Pipeline by Indication, 2015 8
Immunovaccine, Inc. - Pipeline by Stage of Development, 2015 9
Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2015 10
Immunovaccine, Inc. - Partnered Products in Pipeline, 2015 11
Immunovaccine, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 12
Immunovaccine, Inc. - Out-Licensed Products in Pipeline, 2015 13
Immunovaccine, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 14
Immunovaccine, Inc. - Phase II, 2015 15
Immunovaccine, Inc. - Phase I, 2015 16
Immunovaccine, Inc. - Preclinical, 2015 17
Immunovaccine, Inc. - Discovery, 2015 18
Immunovaccine, Inc. - Pipeline by Target, 2015 36
Immunovaccine, Inc. - Pipeline by Route of Administration, 2015 37
Immunovaccine, Inc. - Pipeline by Molecule Type, 2015 38
Immunovaccine, Inc. - Recent Pipeline Updates, 2015 39
Immunovaccine, Inc. - Dormant Developmental Projects,2015 45
Immunovaccine, Inc. - Discontinued Pipeline Products, 2015 46

List of Figures
Immunovaccine, Inc. - Pipeline by Top 10 Indication, 2015 7
Immunovaccine, Inc. - Pipeline by Stage of Development, 2015 9
Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2015 10
Immunovaccine, Inc. - Partnered Products in Pipeline, 2015 11
Immunovaccine, Inc. - Pipeline by Top 10 Target, 2015 36
Immunovaccine, Inc. - Pipeline by Top 10 Route of Administration, 2015 37
Immunovaccine, Inc. - Pipeline by Top 10 Molecule Type, 2015 38

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing